Vivos Therapeutics Inc. (VVOS): Price and Financial Metrics


Vivos Therapeutics Inc. (VVOS): $4.94

-0.74 (-13.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VVOS Stock Price Chart Interactive Chart >

Price chart for VVOS

VVOS Price/Volume Stats

Current price $4.94 52-week high $14.41
Prev. close $5.68 52-week low $4.88
Day low $4.88 Volume 402,200
Day high $5.67 Avg. volume 184,528
50-day MA $6.52 Dividend yield N/A
200-day MA $0.00 Market Cap 112.69M

Vivos Therapeutics Inc. (VVOS) Company Bio


Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.


VVOS Latest News Stream


Event/Time News Detail
Loading, please wait...

VVOS Latest Social Stream


Loading social stream, please wait...

View Full VVOS Social Stream

Latest VVOS News From Around the Web

Below are the latest news stories about Vivos Therapeutics Inc that investors may wish to consider to help them evaluate VVOS as an investment opportunity.

Is Vivos Therapeutics, Inc. (VVOS) A Good Stock To Buy?

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

Yahoo | June 15, 2021

Vivos Therapeutics Founder & Chief Medical Officer Releases New Book Highlighting His Groundbreaking Work

HIGHLANDS RANCH, Colo., May 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that the Company’s Founder and Chief Medical Officer, Dr. G. Dave Singh, DMD, Ph.D., DDSc., has released a new book to help doctors and dentists better understand how to address underlying craniofacial conditions that affect a patient’s overall airway, breathing and sleep health. Dr. Singh’s book, titled, Pneumopedics and Craniofacial Epigenetics, covers craniofacial growth and developmental genetics, and addresses the c...

Yahoo | May 26, 2021

Vivos Therapeutics Reports First Quarter 2021 Financial Results and Operational Update

Management to Host Conference Call Today at 5:00 pm ETHIGHLANDS RANCH, Colo., May 17, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today reported financial results and operating highlights for the first quarter ended March 31, 2021. Financial and Operating Highlights: Revenue was $3.4 million for the first quarter of 2021, an 8% increase compared to $3.2 million for the first quarter of 2020;Gross profit was $2.7 million for the first quarter of 2021, an 11% increase compared to gross profit of $2.4 million for t...

Yahoo | May 17, 2021

Vivos Therapeutics Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 17, 2021 / Vivos Therapeutics Inc (NASDAQ:VVOS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 17, 2021 at 5:00 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

Yahoo | May 17, 2021

What Type Of Shareholders Own The Most Number of Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares?

The big shareholder groups in Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) have power over the company. Institutions often...

Yahoo | May 14, 2021

Read More 'VVOS' Stories Here

VVOS Price Returns

1-mo -12.87%
3-mo -30.42%
6-mo -31.39%
1-year N/A
3-year N/A
5-year N/A
YTD -16.41%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6618 seconds.